Back to top
more

iRhythm Technologies (IRTC)

(Real Time Quote from BATS)

$157.88 USD

157.88
26,564

-2.46 (-1.53%)

Updated Aug 6, 2025 10:18 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

iRhythm Technologies (IRTC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

iRhythm Technologies (IRTC) delivered earnings and revenue surprises of +39.62% and +7.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will iRhythm Technologies (IRTC) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

iRhythm Technologies (IRTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sridatri Sarkar headshot

Tempus AI Gains FDA Nod Amid Booming AI ECG Market Momentum

by Sridatri Sarkar

TEM secures FDA clearance for its AI-powered ECG tool targeting heart failure, as AI ECG adoption accelerates.

Urmimala Biswas headshot

TEM Shares Surge on New AI Breakthrough: Should Investors Jump In?

by Urmimala Biswas

TEM stock rallies 7.3% after the FDA clears its second cardiology AI tool, witnessing a 48% surge in just three months.

Indrajit Bandyopadhyay headshot

DOCS vs. IRTC: Who Will Win High-Stakes AI Showdown in Digital Health?

by Indrajit Bandyopadhyay

DOCS and IRTC are redefining digital health with AI, but only one is winning big with investors in 2025's market surge.

Urmimala Biswas headshot

Innovation Fuels Rally for Tempus AI: Should You Buy the Stock Today?

by Urmimala Biswas

Tempus AI surges 12.5% on new AI tools, a $200M AstraZeneca deal, and clinical data expansion- but is it time to buy?

Urmimala Biswas headshot

After 92% YTD Surge, Is Tempus AI a Buy on Trump's Executive Order?

by Urmimala Biswas

President Donald Trump's new executive order aiming to cut U.S. drug prices could benefit Tempus AI.

Zacks Equity Research

IRhythm Technologies (IRTC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

iRhythm Technologies (IRTC) delivered earnings and revenue surprises of -6.74% and 3.34%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS

by Zacks Equity Research

Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS are included in this Analyst Blog.

Urmimala Biswas headshot

Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?

by Urmimala Biswas

TEM stock rises for three successive days. Should you expect more upside ahead, or is it time to dump Tempus AI?

Urmimala Biswas headshot

Tempus AI Surges 43% YTD: Is it the Right Time to Invest in the Stock?

by Urmimala Biswas

The February 2025 acquisition of Ambry Genetics further expands TEM's genomics capabilities with a West Coast lab and enhanced inherited risk testing.

Urmimala Biswas headshot

Tempus AI Surges 40% YTD: Are New Strategic Deals a Buy Signal?

by Urmimala Biswas

The market's appetite for AI applications in healthcare is rapidly increasing, with TEM emerging as a top contender in this high-growth sector.

Zacks Equity Research

iRhythm Technologies (IRTC) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

iRhythm Technologies (IRTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

DexCom CGM Sensor Sales to Continue Despite FDA Warning Letter

by Zacks Equity Research

DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising competition pose challenges.

Urmimala Biswas headshot

Tempus AI Falls 15% on Weak Q4 but EBITDA View Strong: Buy the Dip?

by Urmimala Biswas

The acquisition of Ambry Genetics strengthens Tempus AI's genomics capabilities by adding a West Coast lab and expanding inherited risk testing.

Zacks Equity Research

IRhythm Technologies (IRTC) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 103.33% and 4.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will iRhythm Technologies (IRTC) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

IRhythm Technologies (IRTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Inspire Medical Systems (INSP) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Inspire (INSP) delivered earnings and revenue surprises of 55.41% and 0.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

The Zacks Analyst Blog Highlights Tempus AI, iRhythm Technologies and SOPHiA GENETICS

by Zacks Equity Research

Tempus AI, iRhythm Technologies and SOPHiA GENETICS are part of the Zacks top Analyst Blog.

Urmimala Biswas headshot

Tempus AI Stock Surges 23% in 6 Months: Should You Snap It Up Now?

by Urmimala Biswas

TEM's cutting-edge product lines and strategic plans are positioning it for long-term success.

Zacks Equity Research

IRhythm Technologies (IRTC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

iRhythm Technologies (IRTC) delivered earnings and revenue surprises of -129.09% and 0.17%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

iRhythm Technologies (IRTC) Soars 21.7%: Is Further Upside Left in the Stock?

by Zacks Equity Research

iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

iRhythm Technologies Stock Rises Post FDA Clearance for Zio AT

by Zacks Equity Research

IRTC receives FDA 510(k) clearance for prior design modifications to its Zio AT device, reinforcing its commitment to quality and compliance.

Zacks Equity Research

iRhythm's Zio ECG System Gets Approval in Japan, Stock Falls

by Zacks Equity Research

IRTC's Zio ECG monitoring system gets approval in Japan, marking a significant step in revolutionizing arrhythmia diagnostics with AI-powered technology.